First AD

Second AD

Multiple Myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Insights Video Series

Recent Advances in The Treatment of Multiple Myeloma: Expert and Patient Perspectives

Krina Patel, MD, details the three- and four-drug regimen first-line treatment options for transplant-eligible newly-diagnosed multiple myeloma and how to make an appropriate treatment decision.

Induction Regimen Options for Patients with Transplant-Eligible Newly-Diagnosed Multiple Myeloma (NDMM)

Introduction to Multiple Myeloma and Resources for Patient Education after Diagnosis

The Role of Stem Cell Transplant in the NDMM Treatment Landscape

Optimal Treatment Selection for Patients with NDMM: Updates from IMS 2022

Available Induction Treatment Regimens for Patients with Transplant-Ineligible MM

Key Considerations for Patients with Multiple Myeloma During the Treatment Journey

Treatment Options for MM at Early Relapse

Unmet Needs in the Treatment of NDMM and R/R MM and Clinical Pearls for Community Oncologists